• Jiaojiao Deng, Lingyang Hua, Liuguan Bian, Hong Chen, Ligang Chen, Hongwei Cheng, Changwu Dou, Dangmurenjiapu Geng, Tao Hong, Hongming Ji, Yugang Jiang, Qing Lan, Gang Li, Zhixiong Liu, Songtao Qi, Yan Qu, Songsheng Shi, Xiaochuan Sun, Haijun Wang, Yongping You, Hualin Yu, Shuyuan Yue, Jianming Zhang, Xiaohua Zhang, WangShuoSDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China., Ying Mao, Ping Zhong, Ye Gong, and Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Association.
• Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
• Chin. Med. J. 2022 Aug 20; 135 (16): 189419121894-1912.

AbstractMeningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations. The fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), published in 2021, introduces major changes that advance the role of molecular diagnostics in meningiomas. To follow the revision of WHO CNS5, this expert consensus statement was formed jointly by the Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Association together with neuropathologists and evidence-based experts. The consensus provides reference points to integrate key biomarkers into stratification and clinical decision making for meningioma patients.RegistrationPractice guideline REgistration for transPAREncy (PREPARE), IPGRP-2022CN234.Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

14 keywords...

hide…